Welcome to our dedicated page for Takeda Pharm news (Ticker: TAK), a resource for investors and traders seeking the latest updates and insights on Takeda Pharm stock.
The TAK news page on Stock Titan aggregates company-specific coverage for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK). Takeda’s own disclosures describe it as a values-based, R&D-driven biopharmaceutical company headquartered in Japan, with core therapeutic and business areas in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Because of this broad focus and active pipeline, Takeda generates frequent news across clinical, regulatory, partnership and financial topics.
Recent press releases highlight late-stage clinical data and regulatory plans for several key programs. In neuroscience, Takeda has presented Phase 3 results for oveporexton (TAK-861), an investigational oral orexin receptor 2 agonist for narcolepsy type 1, showing statistically significant improvements in excessive daytime sleepiness, cataplexy and quality-of-life measures versus placebo. In immunology and dermatology, the company has reported pivotal Phase 3 data for zasocitinib (TAK-279), an investigational highly selective oral TYK2 inhibitor in moderate-to-severe plaque psoriasis, with studies meeting all primary and ranked secondary endpoints.
Takeda news also covers hematology and rare disease developments. Together with Protagonist Therapeutics, the company has released Phase 3 VERIFY and long-term THRIVE data for rusfertide, an investigational hepcidin mimetic for polycythemia vera, demonstrating durable hematocrit control, reduced phlebotomy requirements and maintained patient-reported outcome improvements. In nephrology, Takeda has shared Phase 1b data for mezagitamab (TAK-079) in primary IgA nephropathy, showing stable kidney function and sustained reductions in proteinuria and Gd-IgA1 levels up to 18 months after the last dose.
In vaccines, Takeda has announced seven-year Phase 3 TIDES trial data for its dengue vaccine QDENGA (TAK-003), reinforcing sustained protection against virologically confirmed dengue and dengue-related hospitalizations and supporting a two-dose regimen. Corporate and pipeline news includes strategic oncology collaborations, such as the global partnership with Innovent Biologics for late-stage assets IBI363 and IBI343, and financial updates on revenue trends, generic erosion impacts and revised full-year forecasts.
Investors and followers of TAK can use this news feed to track Takeda’s clinical milestones, regulatory filings, strategic alliances, portfolio prioritization decisions and IFRS-based financial disclosures as they are reported in press releases and SEC Form 6-K submissions.
Takeda Pharmaceutical Company applied for selection to the Prime Market of the Tokyo Stock Exchange (TSE). The decision was made during the Board of Directors Meeting on September 29-30, 2021, following the TSE's initial assessment on July 9, 2021, confirming compliance with listing requirements. The company also submitted its Corporate Governance Report based on an updated governance code. Enhancements to governance transparency include updated documents available on its corporate website. This move aims to maximize corporate value and strengthen stakeholder engagement.
Takeda Pharmaceutical Company announced a share buyback plan of up to 100 billion yen, aiming to acquire up to 35 million shares, representing 2.23% of outstanding shares. The initiative is designed to enhance capital efficiency and improve shareholder returns, indicating confidence in the company's cash generation capabilities. The buyback is scheduled from November 2, 2021 to April 29, 2022 and will not affect Takeda's existing deleveraging goals. The company's strong pipeline includes approximately 40 new molecular entities.
Takeda Pharmaceutical Company (NYSE:TAK) reported impressive financial results for H1 FY2021, with a 12.8% increase in reported revenue, amounting to 1,794.4 billion yen ($16.1B), and a 6.8% rise in underlying revenue of 1,661.4 billion yen ($14.9B). The company confirmed its full-year guidance aiming for a 30% core operating profit margin. Further growth is expected through its 14 global brands, which contributed 42% of total core revenue, and a share buyback of up to 100 billion yen highlights confidence in business strategy.
Takeda Pharmaceutical Company has announced its acquisition of GammaDelta Therapeutics, a biotech focused on γδ T cell immunotherapy. This strategic move expands Takeda's capabilities in the immuno-oncology space, targeting solid tumors and blood cancers. The acquisition follows a successful collaboration established in 2017 and involves pre-negotiated upfront and milestone payments. With a focus on off-the-shelf therapies, Takeda aims to enhance patient access to innovative cancer treatments. The deal is set to finalize in Q1 of Takeda's fiscal year 2022, pending regulatory review.
BioLife Plasma Services has opened its first plasma donation center in Worcester, Massachusetts, aiming to meet the urgent demand for plasma-derived therapies for rare and chronic conditions. This center is part of a growing network that currently includes over 160 centers across the U.S. BioLife plans to open additional centers, contributing $2-3 million annually to local communities and creating around 70 jobs per location. The center will begin operations on October 16, with an emphasis on providing an industry-leading donor experience.
Takeda announced that the FDA's Antimicrobial Drugs Advisory Committee unanimously recommended maribavir (TAK-620) for treating refractory cytomegalovirus (CMV) infections in transplant recipients. If approved, maribavir will be the first treatment indicated for adults with this condition. The recommendation is based on results from the Phase 2 and Phase 3 TAK-620-303 (SOLSTICE) trials. The FDA is currently conducting a Priority Review of the New Drug Application (NDA) for maribavir, which has also received Breakthrough Therapy and Orphan Drug designations.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced the suspension of patient dosing in its Phase 2 studies of TAK-994, an investigational oral orexin agonist, due to a safety signal. This premature cessation aims to reassess the treatment’s benefit/risk profile. Takeda remains committed to patient safety and plans to evaluate all available data for future development decisions regarding TAK-994. The company continues its focus on its orexin franchise, including TAK-861, which is in Phase 1 development.
Summary not available.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced new partnerships with IntraHealth International, Jhpiego, Pathfinder International, and the World Food Programme, expanding its Global CSR Program. This initiative has contributed JPY 16.5 billion to 20 programs in 72 countries since its launch in 2016. Key commitments include JPY 953 million for nursing education in West Africa and JPY 1.3 billion for the World Food Programme’s logistics project in Ghana. These partnerships aim to enhance healthcare access and improve health systems, benefiting millions globally.
Mirum Pharmaceuticals has entered into an exclusive licensing agreement with Takeda Pharmaceutical Company for the development and commercialization of maralixibat in Japan. This investigational drug targets rare liver diseases such as Alagille syndrome, progressive familial intrahepatic cholestasis, and biliary atresia. Takeda will oversee regulatory approval and conduct clinical studies. Mirum has also submitted a new drug application for maralixibat in the U.S., with a priority review by the FDA expected by September 29, 2021.